Elanco Animal Health Reports Second Quarter 2026 Results

Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target

* Second Quarter 2026 Financial Results: * Revenue of $1,368 million, an increase of 10% year-over-year; 8% organic constant currency growth * Reported Net Income of $54 million, Adjusted Net Income of $174 million * Adjusted EBITDA of $288 million; Adjusted EBITDA Margin of 21.2% * Reported EPS of $0.11, Adjusted EPS of $0.34 * Net leverage ratio of 3.1x Adjusted EBITDA * Full Year 2026 Guidance: * Raising innovation revenue target to $1.25 billion * Raising revenue guidance to $5.09 billion to $5.14 billion, or 6% to 7% organic constant currency growth * Raising Adjusted EBITDA to $1.01 billion to $1.035 billion, a year-over-year increase of 13% at midpoint * Raising Adjusted EPS to $1.10 to $1.16, a year-over-year increase of 20% at midpoint * Improving year-end net leverage ratio target to approximately 3.0x Adjusted EBITDA INDIANAPOLIS, Aug. 5, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the second quarter of 2026, provided guidance for the third quarter of 2026, and updated guidance for the full year 2026.